Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benzoyl-tyrosine-alanine-fluoro-methyl ketone is a synthetic peptidyl fluoromethyl ketone (PFMK), a class of small molecules known for their ability to inhibit hydrolytic enzymes. Specifically, these compounds act as potent inhibitors of serine and cysteine proteases. The insertion of a fluorine atom adjacent to the C-terminal ketone moiety enhances the reactivity and selectivity of the compound towards nucleophiles, often leading to irreversible inhibition, particularly for mono-fluorinated derivatives. PFMKs are widely utilized in medicinal chemistry as probes to investigate proteolytic activity and to elucidate the roles of proteases in various diseases. They hold potential for the development of treatments for conditions such as cancer and viral infections, where protease activity is implicated in disease progression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Benzoyl-tyrosine-alanine-fluoro-methyl ketone.